


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 0 or 1;

n = 0 or 1;

A is selected from the group consisting of: $-\text{CO}_2\text{H}$, $-\text{PO}_3\text{H}_2$, $-\text{PO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{PO}(\text{C}_{1-3}\text{alkyl})\text{OH}$ and 1H-tetrazol-5-yl;

R1 and R2 are each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-\text{CO}_2\text{H}$ and C1-4alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo;

R3 is selected from the group consisting of: hydrogen and C1-4alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R⁴ is independently selected from the group consisting of: halo, C₁₋₄alkyl and C₁₋₃alkoxy, said C₁₋₄alkyl and C₁₋₃alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,


C is selected from the group consisting of:

- (1) ~~C₁₋₆alkyl, C₁₋₆alkoxy, (C=O)C₁₋₆alkyl or CHOH-C₁₋₆alkyl, said C₁₋₆alkyl, C₁₋₆alkoxy, (C=O)C₁₋₆alkyl and CHOH-C₁₋₆alkyl optionally substituted with phenyl, and~~
- (2) ~~phenyl or HET, wherein HET is thienyl, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl[[,]] and C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups,~~

or C is not present; and

~~when C is not present then B is selected from the group consisting of: phenyl, C₅₋₁₆alkyl, C₅₋₁₆alkenyl, C₅₋₁₆alkynyl, CHOH-C₄₋₁₅alkyl, CHOH-C₄₋₁₅alkenyl, CHOH-C₄₋₁₅alkynyl, C₄₋₁₅alkoxy, O-C₄₋₁₅alkenyl, O-C₄₋₁₅alkynyl, C₄₋₁₅alkylthio, S-C₄₋₁₅alkenyl, S-C₄₋₁₅alkynyl, CH₂-C₃₋₁₄alkoxy, CH₂-O-C₃₋₁₄alkenyl, CH₂-O-C₃₋₁₄alkynyl, (C=O)-C₄₋₁₅alkyl, (C=O)-C₄₋₁₅alkenyl, (C=O)-C₄₋₁₅alkynyl, (C=O)-O-C₃₋₁₄alkyl, (C=O)-O-C₃₋₁₄alkenyl, (C=O)-O-C₃₋₁₄alkynyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkenyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkynyl, N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkyl, N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkenyl and N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkynyl,~~

~~when C is phenyl or HET then B is selected from the group consisting of: C₁₋₆alkyl, C₁₋₅alkoxy, (C=O)-C₁₋₅alkyl, (C=O)-O-C₁₋₄alkyl, (C=O)-N(R⁶)(R⁷)-C₁₋₄alkyl,~~



when ~~C~~ is ~~C₁₋₈alkyl, C₁₋₈alkoxy, (C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl~~ then ~~B~~ is phenyl; and

~~R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁₋₉alkyl and (CH₂)_p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C₁₋₃alkyl and C₁₋₃alkoxy, each optionally substituted with 1-3 halo groups.~~

2. (currently amended) The compound according to Claim 1 wherein:

Ar is phenyl;

the group -B-C is attached to the phenyl ring at the 3- or 4-position;

~~C is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups,~~

or ~~C~~ is not present;

when ~~C~~ is not present then ~~B~~ is selected from the group consisting of: ~~C₇₋₁₂alkyl, C₇₋₁₂alkenyl, C₇₋₁₂alkynyl, C₆₋₁₁alkoxy, -O-C₆₋₁₁alkenyl, -O-C₆₋₁₁alkynyl, (C=O)-C₆₋₁₁alkyl, (C=O)-~~

~~C₆₋₁₁alkenyl, (C=O)-C₆₋₁₁alkynyl, (C=O)-O-C₅₋₁₀alkyl, (C=O)-O-C₅₋₁₀alkenyl, and (C=O)-O-C₅₋₁₀alkynyl and C is not present;~~

and

~~when C is phenyl or HET then B is selected from the group consisting of C₁₋₅alkyl, C₁₋₄alkoxy, (C=O)-C₁₋₄alkyl, (C=O)-O-C₁₋₃alkyl, phenyl and HET.~~

3. (canceled)

4. (original) The compound according to Claim 1 wherein m is 0.

5. (original) The compound according to Claim 1 wherein m is 1.

6. (original) The compound according to Claim 1 wherein n is 0.

7. (original) The compound according to Claim 1 wherein n is 1.

8. (canceled)

9. (currently amended) The compound according to Claim 1 wherein:

B is methoxy and **C** is HET, wherein said HET is thienyl substituted with phenyl and C₁₋₄alkyl, said C₁₋₄alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, ~~and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups.~~


10 to 20. (canceled)

21. (currently amended) The compound according to Claim ~~20~~ 4 wherein R¹, R² and R³ are hydrogen.

22. (original) The compound according to Claim 2 wherein the group **-B-C** is attached to the phenyl ring at the 4-position.

23. (canceled)

24. (original) A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$n = 0$ or 1 ;

R^3 is selected from the group consisting of: hydrogen and C_{1-4} alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;







each R^4 is independently selected from the group consisting of: halo, C_{1-4} alkyl and C_{1-3} alkoxy, said C_{1-4} alkyl and C_{1-3} alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.


25. (original) The compound according to Claim 24 wherein n is 0 .

26. (original) The compound according to Claim 24 wherein n is 1 .

27. (original) The compound according to Claim 24 wherein R³ is hydrogen.

28. (currently amended) The compound according to Claim 24 selected from the following table:



or a pharmaceutically acceptable salt of any of the foregoing compounds.

29 to 33. (canceled)

34. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

35 to 47. (canceled)